High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis

Overview

The need for a standardized treatment protocol for multidrug resistant tuberculosis (MDR-TB) in resource-limited countries is being increasingly recognized. This single center, double blind, randomized controlled trial was designed to compare the time required for sputum culture conversion and extent of radiological improvement in cases of MDR pulmonary tuberculosis when isoniazid was included (both at a regular dose and at a high dose) as an adjuvant to the standardized second line of treatment. The study was designed to test the hypothesis that inclusion of high-dose isoniazid will enhance the effectiveness of the second line of treatment in cases of MDR-TB without significantly increasing the toxicity.

Full Title of Study: “A Randomized Control Trial Of High-Dose Isoniazid Adjuvant Therapy For Multidrug Resistant Tuberculosis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)

Detailed Description

Tuberculosis was declared a global emergency by the World Health Organization (WHO) in 1993. The global problem of tuberculosis is further complicated by a substantial increase in drug resistant tuberculosis. Available data suggest that drug resistant TB especially multi drug resistant may represent a public health threat in areas with a high prevalence of tuberculosis, suboptimal TB control programmes and/ or HIV. The cure rate of these cases has been reported to be lower than for non-drug resistant TB with a failure rate of 44%. New therapies for MDR-TB have not been introduced since the fluoroquinolones in the 1970s. Strains of Mycobacterium Tuberculosis (M. tub.) in H resistant cases often contain mixture of susceptible & resistant organisms. Use of high dose H (16- 20 mg/kg) can eliminate susceptible & those with low level resistance4. This Study was done to evaluate the role of isoniazid (INH) at high & normal dosages as an adjuvant therapy in treatment of patients with persistent culture positive pulmonary tuberculosis despite 6 months of continuous first line antitubercular treatment and on culture at least resistant to isoniazid and rifampicin.

Interventions

  • Drug: Isoniazid
    • High-dose isoniazid (16-18 mg/kg/day) in addition to standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day) Regular dose isoniazid (5 mg/kg/day) in addition to standard regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)
  • Drug: Placebo
    • Similar appearing and similarly packaged placebo tablets in addition to the standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)

Arms, Groups and Cohorts

  • Experimental: 1
  • Active Comparator: 2
  • Placebo Comparator: 3

Clinical Trial Outcome Measures

Primary Measures

  • Time to sputum culture conversion
    • Time Frame: 1 year

Secondary Measures

  • Extent of radiological improvement
    • Time Frame: 1 year
  • Proportion with peripheral neuropathy
    • Time Frame: 1 year
  • Proportion with hepatotoxicity
    • Time Frame: 1 year

Participating in This Clinical Trial

Inclusion Criteria

  • Consecutive patients reporting to the study center – Sputum-positive for acid-fast bacilli – HIV-uninfected – MDR-TB defined as resistance to at least the following two drugs: Isoniazid and Rifampicin. Exclusion Criteria:

  • Unwilling to give consent – Abnormal renal or hepatic profile – History suggestive of isoniazid hypersensitivity – Pregnancy – Lactating mother – Previous history of taking any of the following: kanamycin, prothionamide, levofloxacin, cycloserine and p-aminosalicylic acid

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • GSVM Medical College
  • Overall Official(s)
    • Subodh Katiyar, MD, Study Chair, GSVM Medical College, Kanpur, India
    • Shivesh Prakash, MBBS, Principal Investigator, GSVM Medical College, Kanpur, India
    • Shailesh Bihari, MD, Principal Investigator, GSVM Medical College, Kanpur, India
    • Hemant Kulkarni, MD, Principal Investigator, Lata Medical Research Foundation, Nagpur, India
    • Manju Mamtani, MD, Principal Investigator, Lata Medical Research Foundation, Nagpur, India

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.